We tested VPF potency across distinctive NB subtypes, more specifically in MYCN-non-amplified (MYCN-NA) and predominantly YAP-positive, as well as in MYCN-amplified (MYCN-A) and predominantly YAP-negative NB cell lines. This evidence concerns the gene MYCN and neuroblastoma.